Spiramycine Métronidazole CristerS Uses

Was this medicine useful for you?
sponsored

Spiramycine Métronidazole CristerS indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Metronidazole (Spiramycine Métronidazole CristerS) is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of thetrichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).Metronidazole (Spiramycine Métronidazole CristerS) is indicated in the treatment of asymptomatic females when the organism is associated with endocervi-citis, cervicitis, or cervical erosion.

Metronidazole (Spiramycine Métronidazole CristerS) is indicated in the treatment of acute intestinal amebiasis (amebic dysen-tery)and amebic liver abscess.

In amebic liver abscess, Metronidazole (Spiramycine Métronidazole CristerS) therapy does not obviate the need for aspiration or drainage of pus.

Metronidazole (Spiramycine Métronidazole CristerS) is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole (Spiramycine Métronidazole CristerS) therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to Flagyl.

INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis,B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostrid-ium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species.

SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger,Peptostreptococcus species, and Fusobacte-rium species.

GYNECOLOGIC INFECTIONS, including endo-metritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcusniger, and Pepto-streptococcus species.

BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group, and Clos-tridium species.

BONE AND JOINT INFECTIONS, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group.

CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B.fragilis group.

LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group.

ENDOCARDITIS caused by Bacteroides species including the B.fragilis group.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole (Spiramycine Métronidazole CristerS) and other antibacterial drugs, Metronidazole (Spiramycine Métronidazole CristerS) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Spiramycine Métronidazole CristerS interactions

sponsored

Metronidazole (Spiramycine Métronidazole CristerS) has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when Metronidazole (Spiramycine Métronidazole CristerS) (Metronidazole (Spiramycine Métronidazole CristerS)) is prescribed for patients on this type of anticoagulant therapy.

The simultaneous administration of drugs that induce microsomal liver enzymes, such as phe-nytoin or phenobarbital, may accelerate the elimination of Metronidazole (Spiramycine Métronidazole CristerS), resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.

The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may prolong the half-life and decrease plasma clearance of Metronidazole (Spiramycine Métronidazole CristerS). In patients stabilized on relatively high doses of lithium, short-term Metronidazole (Spiramycine Métronidazole CristerS) therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum cre-atinine levels should be obtained several days after beginning Metronidazole (Spiramycine Métronidazole CristerS) to detect any increase that may precede clinical symptoms of lithium intoxication.

Alcoholic beverages should not be consumed during Metronidazole (Spiramycine Métronidazole CristerS) therapy and for at least one day afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur.

Psychotic reactions have been reported in alcoholic patients who are using Metronidazole (Spiramycine Métronidazole CristerS) and disulfiram concurrently. Metronidazole (Spiramycine Métronidazole CristerS) should not be given to patients who have taken disulfiram within the last two weeks.

Spiramycine Métronidazole CristerS side effects

sponsored

Two serious adverse reactions reported in patients treated with Metronidazole (Spiramycine Métronidazole CristerS) (Metronidazole (Spiramycine Métronidazole CristerS)) have been convulsive seizures and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity. Since persistent peripheral neuropathy has been reported in some patients receiving prolonged administration of Metronidazole (Spiramycine Métronidazole CristerS), patients should be specifically warned about these reactions and should be told to stop the drug and report immediately to their physicians if any neu-rologic symptoms occur.

The most common adverse reactions reported have been referable to the gastrointestinal tract, particularly nausea reported by about 12% of patients, sometimes accompanied by headache, anorexia, and occasionally vomiting; diarrhea; epi-gastric distress; and abdominal cramping. Constipation has also been reported.

The following reactions have also been reported during treatment with Metronidazole (Spiramycine Métronidazole CristerS) (Metronidazole (Spiramycine Métronidazole CristerS)):

Mouth: A sharp, unpleasant metallic taste is not unusual. Furry tongue, glossitis, and sto-matitis have occurred; these may be associated with a sudden overgrowth of Candida which may occur during therapy.

Hematopoietic: Reversible neutropenia (leuko-penia); rarely, reversible thrombocytopenia.

Cardiovascular: Flattening of the T-wave may be seen in electrocardiographic tracings.

Central Nervous System: Convulsive seizures, peripheral neuropathy, dizziness, vertigo, incoordination, ataxia, confusion, irritability, depression, weakness, and insomnia.

Hypersensitivity: Urticaria, erythematous rash, flushing, nasal congestion, dryness of the mouth (or vagina or vulva), and fever.

Renal: Dysuria, cystitis, polyuria, incontinence, and a sense of pelvic pressure. Instances of darkened urine have been reported by approximately one patient in 100,000. Although the pigment which is probably responsible for this phenomenon has not been positively identified, it is almost certainly a metabolite of Metronidazole (Spiramycine Métronidazole CristerS) and seems to have no clinical significance.

Other: Proliferation of Candida in the vagina, dyspareunia, decrease of libido, proctitis, and fleeting joint pains sometimes resembling &ldquoserum sickness.” If patients receiving Metronidazole (Spiramycine Métronidazole CristerS) drink alcoholic beverages, they may experience abdominal distress, nausea, vomiting, flushing, or headache. A modification of the taste of alcoholic beverages has also been reported. Rare cases of pan-creatitis, which generally abated on withdrawal of the drug, have been reported.

Crohn’s disease patients are known to have an increased incidence of gastrointestinal and certain extraintestinal cancers. There have been some reports in the medical literature of breast and colon cancer in Crohn’s disease patients who have been treated with Metronidazole (Spiramycine Métronidazole CristerS) at high doses for extended periods of time. A cause and effect relationship has not been established. Crohn’s disease is not an approved indication for Metronidazole (Spiramycine Métronidazole CristerS).

Spiramycine Métronidazole CristerS contraindications

sponsored

Metronidazole (Spiramycine Métronidazole CristerS) is contraindicated in patients with a prior history of hypersensitivity to Metronidazole (Spiramycine Métronidazole CristerS) or other nitroimidazole derivatives.

Active ingredient matches for Spiramycine Métronidazole CristerS:

Metronidazole/Spiramycin in France.


List of Spiramycine Métronidazole CristerS substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
Tablet, Film-Coated; Oral; Metronidazole 125 mg; Spiramycin 750, 000 IU
Tablet, Film-Coated; Oral; Metronidazole 250 mg; Spiramycin 1, 500, 000 IU
Spiranisol Forte 2 Blister x 10 Tablet
Spiranisol 2 Blister x 10 Tablet
Spirumet 1 Blister x 10 Tablet
Spyforce 1 Box
Tablet; Oral; Metronidazole 25 mg; Spiramycin 150, 000 IU / dose
Tablet; Oral; Metronidazole 125 mg; Spiramycin 750, 000 IU / dose
Tablet; Oral; Metronidazole 250 mg; Spiramycin 1, 500, 000 IU / dose
Viagogyl 2 Blister x 10 Tablet
Zidocin DHG 2 Blister x 10 Tablet
Zolgyl 2 Blister x 10 Tablet

References

  1. DailyMed. "BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "metronidazole". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "metronidazole". http://www.drugbank.ca/drugs/DB00916 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Spiramycine Métronidazole CristerS are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Spiramycine Métronidazole CristerS. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 28 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved